Immuron Limited (IMRN)

NASDAQ: IMRN · IEX Real-Time Price · USD
2.75
+0.15 (5.77%)
At close: Aug 15, 2022 3:54 PM
2.76
+0.01 (0.36%)
After-hours: Aug 15, 2022 4:00 PM EDT
5.77%
Market Cap 16.77M
Revenue (ttm) 254,594
Net Income (ttm) -3.18M
Shares Out 6.10M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,148
Open 2.60
Previous Close 2.60
Day's Range 2.49 - 2.85
52-Week Range 2.00 - 5.20
Beta 1.73
Analysts n/a
Price Target n/a
Earnings Date Aug 30, 2022

About IMRN

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive func... [Read more...]

Industry Biotechnology
Founded 1994
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol IMRN
Full Company Profile

Financial Performance

In 2021, Immuron's revenue was 145,776, a decrease of -94.21% compared to the previous year's 2.52 million. Losses were -8.38 million, 186.4% more than in 2020.

Financial numbers in AUD Financial Statements

News

Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic

MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic...

Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic...

US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™

Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the comparative efficacy of Travel...

Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer

MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics...

Immuron Travelan® Global sales up 216%

Key Highlights:

Appointment of Paul Brennan as Non-Executive Director

MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeuti...

Immuron Receives AUD $306,154 R&D Tax Concession Refund

MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic...

Immuron Receives European Patent on Drug Composition to Treat Travelers' Diarrhea

MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic...

IMRN Stock Alert: What Is the Huge Catalyst Sending Immuron Soaring?

Today marks one of the best days for IMRN stock in a long time, with shares surging nearly 50% on the back of some impressive news. The post IMRN Stock Alert: What Is the Huge Catalyst Sending Immuron S...

Here is why Immuron is up 30% on Wednesday

Immuron Limited (NASDAQ: IMRN) went up 30% after it announced that it had received $6.2 million from the Department of Defense to conduct clinical research on a dosing regimen for Travelan.  This new re...

Immuron Shares Rally On US Department Of Defense Funding Of A$6.2M

Immuron Limited (NASDAQ: IMRN) has received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing regimen for Travelan more suited for use by the military. The Company ...

Immuron stock rockets after funding by U.S. DoD of new research agreement

Shares of Immuron Ltd. IMRN, +2.67% rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) ...

US DoD Naval Medical Research Center Clinical Update

Key Points

Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies were conducted independently by the Hadassah Medical ...

IMM-124E – Demonstrates Antiviral T-Cell Immunity

Key Points

Immuron Director resignation

MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeuti...

Immuron planned Acquisition of R&D Vaccine Company

MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeuti...

Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference

MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutic...